Can IVIG Cause Seizures?
Yes, IVIG can cause seizures, though this is a rare adverse effect. The primary neurological complication associated with IVIG is aseptic meningitis, which typically resolves without neurological sequelae, but seizures have been documented as a potential adverse event 1.
Documented Neurological Adverse Effects
Aseptic Meningitis Syndrome (AMS)
- AMS is the most commonly reported neurological complication of IVIG therapy, with symptoms typically beginning within several hours to 2 days following treatment 1.
- The condition presents with severe headache, neck stiffness, drowsiness, fever, sensitivity to light, painful eye movements, nausea, and vomiting 1.
- Discontinuation of IVIG treatment results in remission of AMS within several days without permanent neurological damage 2, 1.
- The frequency and risk factors for AMS have been well-documented in the literature 1.
Seizures as an Adverse Event
- Infusion-related seizures have been reported in clinical practice, particularly in pediatric populations receiving IVIG 3.
- In a retrospective study of children with Dravet syndrome receiving IVIG, adverse events included infusion-related fever or seizures in 6 out of 14 individuals 3.
- The FDA drug label for IVIG products lists neurological complications as potential adverse effects, though seizures are not specifically highlighted as a common occurrence 1.
Clinical Context and Risk Factors
High-Risk Populations
- Patients with pre-existing neurological conditions may be at increased risk for seizure activity during IVIG infusion 3.
- Children with epilepsy syndromes receiving IVIG as adjuvant therapy have experienced infusion-related seizures, though distinguishing between disease-related and treatment-related seizures can be challenging 3, 4.
Mechanism Considerations
- The exact mechanism by which IVIG might trigger seizures is not well-established in the literature 1.
- Potential contributing factors include rapid infusion rates, volume overload, electrolyte disturbances (particularly hyponatremia from hyperproteinemia), or immune-mediated inflammatory responses 1.
Monitoring and Management Recommendations
During Infusion
- Monitor patient vital signs throughout the infusion, and slow or stop infusion if adverse reactions occur 1.
- If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient 1.
- The recommended initial infusion rate is 0.01 mL/kg/min (0.5 mg/kg/min), gradually increasing to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if well-tolerated 1.
Patient Counseling
- Instruct patients to immediately report severe headache, neck stiffness, drowsiness, fever, sensitivity to light, painful eye movements, nausea, and vomiting 1.
- These symptoms may indicate aseptic meningitis, which requires prompt evaluation 1.
Important Caveats
- The distinction between IVIG-induced seizures and underlying disease progression can be difficult, particularly in patients receiving IVIG for neurological conditions 3, 5.
- While seizures are a documented adverse effect, they appear to be relatively uncommon compared to other IVIG-related complications such as aseptic meningitis, hemolysis, or thrombosis 1.
- The benefit-risk profile generally favors IVIG use in appropriate indications, as serious neurological complications are rare and typically reversible 2, 1.